Literature DB >> 14609187

Myocardial thallium defects in apical hypertrophic cardiomyopathy are associated with a benign prognosis. Thallium defects in apical hypertrophy.

Kyung-Han Lee1, Hong-Joo Jang, Sang Chul Lee, Young-Hwan Kim, Eun-Jung Lee, Jung-Don Seo, Byung-Tae Kim.   

Abstract

BACKGROUND: We investigated whether myocardial thallium-201 defects in patients with apical hypertrophic cardiomyopathy are associated with an unfavorable clinical outcome, and additionally compared the presence of defects to echocardiography and angiography findings.
METHODS: Dipyridamole thallium-201 single photon emission tomography was performed in 26 apical hypertrophic cardiomyopathy patients, aged 41-78 (22 men, 6 women). Patients with or without perfusion defects were compared for echocardiographic measurements of wall thickness, chamber dimensions, and fractional shortening. Twelve patients underwent coronary angiography. The occurrence of cardiac events was evaluated during clinical follow-up for a mean period of 4.3 +/- 1.9 years (range: 1.0-7.0 year).
RESULTS: Thirteen patients (50%) showed perfusion defects, which were predominantly reversible (fixed in 1) and mostly apical (9 of 13). Patients with and without defects did not differ in symptoms, EKG findings, echocardiographic morphology or fractional shortening (41 +/- 4 vs. 41 +/- 7%). Coronary angiography was normal in all patients in whom it was performed (nine with and three without defects). During follow-up, there were no deaths or myocardial infarction. Of the defect positive group, one case developed paroxysmal supraventricular tachycardia, and another had a cerebrovascular accident. Of the defect negative group, one case developed sick sinus syndrome, while another had a hospital admission for anginal pain.
CONCLUSIONS: While reversible thallium defects in the absence of coronary artery disease occur frequently in patients with apical hypertrophic cardiomyopathy, the prognosis remains benign despite the presence of ischemia and there is no evidence for an association with adverse patient outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14609187     DOI: 10.1023/a:1025807125699

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  24 in total

1.  Apical cardiomyopathy: an important differential diagnosis in ischaemic chest pain.

Authors:  S L Seneviratne; A P Premawardena; G W Ranasinghe; S B Gunatilake; H J de Silva
Journal:  Ceylon Med J       Date:  1996-09

2.  Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome.

Authors:  M Yamada; P M Elliott; J C Kaski; K Prasad; J N Gane; C M Lowe; Y Doi; W J McKenna
Journal:  Eur Heart J       Date:  1998-03       Impact factor: 29.983

3.  [Clinical characteristics and cardiac events in elderly patients with apical hypertrophic cardiomyopathy].

Authors:  Y Suganuma; K Shinmura; H Hasegawa; M Tani; Y Nakamura
Journal:  Nihon Ronen Igakkai Zasshi       Date:  1997-06

Review 4.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

Authors:  B J Maron; R O Bonow; R O Cannon; M B Leon; S E Epstein
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

5.  Serious arrhythmias in patients with apical hypertrophic cardiomyopathy.

Authors:  K Okishige; T Sasano; K Yano; K Azegami; K Suzuki; K Itoh
Journal:  Intern Med       Date:  2001-05       Impact factor: 1.271

6.  Necropsy finding in a patient with apical hypertrophic cardiomyopathy.

Authors:  S Sumino; T Sugimoto; T Koide; S Murao
Journal:  Jpn Heart J       Date:  1985-03

7.  Apical hypertrophic cardiomyopathy and ventricular tachycardia.

Authors:  Y L Doi; N Hamashige; Y Yonezawa; T Ozawa
Journal:  Eur Heart J       Date:  1984-10       Impact factor: 29.983

8.  Apical hypertrophy with massive myocardial fibrosis: comparison with electrocardiographic changes.

Authors:  S Fujimoto; Y Komoto; Y Sakaguchi; R Mizuno; K Dohi; H Nakano
Journal:  Intern Med       Date:  1998-05       Impact factor: 1.271

9.  Apical hypertrophic cardiomyopathy.

Authors:  J Rivera-Diaz; A R Moosvi
Journal:  South Med J       Date:  1996-07       Impact factor: 0.954

10.  [Advanced sequelae of apical hypertrophic cardiomyopathy: report of two cases with wall motion abnormalities].

Authors:  J Kusukawa; M Suwa; Y Nakayama; Y Hirota; K Kawamura; I Adachi; H Akagi
Journal:  J Cardiol       Date:  1988-03       Impact factor: 3.159

View more
  4 in total

1.  Postischemic stunning in apical hypertrophic cardiomyopathy.

Authors:  J Wells Askew; Richard P Umfrid
Journal:  J Nucl Cardiol       Date:  2005 Mar-Apr       Impact factor: 5.952

2.  High probability of disease in angina pectoris patients: is clinical estimation reliable?

Authors:  Poul F Høilund-Carlsen; Allan Johansen; Werner Vach; Henrik Wulff Christensen; Mette Møldrup; Torben Haghfelt
Journal:  Can J Cardiol       Date:  2007-06       Impact factor: 5.223

3.  Hypertrophic cardiomyopathy complicated by left ventricular apical necrosis and aneurysm in a young man: FDG-PET findings.

Authors:  Jong-Seon Park; Ihn-Ho Cho; Dong-Gu Shin; Young-Jo Kim; Gu-Ru Hong; Bong-Sup Shim
Journal:  Korean J Intern Med       Date:  2007-03       Impact factor: 2.884

4.  Detection of apical hypertrophic cardiomyopathy; which is the appropriate imaging modality.

Authors:  E E van der Wall; J J Bax; M J Schalij
Journal:  Int J Cardiovasc Imaging       Date:  2008-10       Impact factor: 2.357

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.